Used in targeted cancer therapies, particularly for prostate and other solid tumors expressing the 158P1D7 antigen. This monoclonal antibody binds specifically to the 158P1D7 cell surface protein, enabling immune-mediated destruction of cancer cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It serves as a key component in the development of antibody-drug conjugates (ADCs), where it delivers cytotoxic agents directly to tumor cells, minimizing damage to healthy tissues. Also utilized in diagnostic imaging to detect tumor expression of the target antigen. Its high specificity makes it valuable in both therapeutic and diagnostic oncology applications.